Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 28 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Orlistat improves weight in obese adolescents

Orlistat improves weight management in obese adolescents compared with placebo, raising no safety issues, although gastrointestinal adverse events are more common with orlistat, reports the latest Journal of the American Medical Association.

News image

fiogf49gjkf04

The prevalence of overweight and obesity in children and adolescents is increasing rapidly.

In this population, behavioral therapy alone has had limited success in providing meaningful, sustained weight reduction.

Pharmacological treatment has not been extensively studied.

Body mass index decreased by 0.6 with orlistat but increased by 0.3 with placebo
Journal of the Medical Association

Dr Chanoine and colleagues determined the efficacy and safety of orlistat in weight management of adolescents.

The investigators conducted a multicenter, randomized, double-blind study at 32 centers in the United States and Canada over 54 weeks from 2000 to 2002.

The investigative team included 539 obese adolescents, aged 12 to 16 years with a body mass index 2 units above the 95th percentile.

The team randomized 357 patients to 120 mg of orlistat or 182 to placebo 3 times daily for 1 year, plus a mildly hypocaloric diet, exercise, and behavioral therapy.

The main outcome measures included by the team were changes in body mass index.

The secondary measures included changes in waist and hip circumference, weight loss, lipid measurements, and glucose and insulin responses to oral glucose challenge.

The investigators found a decrease in body mass index in both treatment groups up to week 12.

After week 12, body mass index in both treatment groups stabilized with orlistat but increased beyond baseline with placebo.

The investigative team found that at the end of the study, body mass index had decreased by 0.6 with orlistat but increased by 0.3 with placebo.

Compared with 16% of the placebo group, the team reported that 27% of participants taking orlistat had a 5% or higher decrease in body mass index.

The investigators also observed that 5% with placebo and 13% receiving orlistat had a 10% or higher decrease in body mass index.

At study end, the investigative team noted that weight had increased 0.5 kg with orlistat and 3 kg with placebo.

The team explained that this difference in weight increase was due to changes in fat mass, shown by using dual-energy x-ray absorptiometry.

The investigators also reported that waist circumference decreased in the orlistat group but increased in the placebo group.

In addition, mild to moderate gastrointestinal tract adverse events were identified in 9% to 50% of the orlistat group and in 1% to 13% of the placebo group.

Dr Chanione and team concluded, “In combination with diet, exercise, and behavioral modification, orlistat statistically significantly improved weight management in obese adolescents compared with placebo.”

“The use of orlistat for 1 year in this adolescent population did not raise major safety issues although gastrointestinal adverse events were more common in the orlistat group.”

JAMA 2005: 293: 2873-83
17 June 2005

Go to top of page Email this page Email this page to a colleague

 28 May 2018 
Therapeutic strategies for HCV
 28 May 2018 
Mesalazine in ulcerative colitis
 28 May 2018 
Technology and management of digestive diseases
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 25 May 2018 
Colorectal cancer–specific mortality
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us